Follow The Filings

XBI SPDR S&P Biotech ETF

Filed as SPDR S&P BIOTECH ETF (ETF), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 5.9%
  • $31M
  • 1 new 1 reduce

In 2026 Q2 Cathie Wood opened a position in SPDR S&P Biotech ETF, while Nathan Fischel trimmed.

Who owns this now

Largest portfolio weights among holders, up to 5.9% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 5.9%

Who owns XBI

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 5.9%, was 9.3% Reduce −38.3% 196,505 $31M History
Cathie Wood, Ark Investment Management <0.01% New <0.01% 94 $15K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Congress

1 member of Congress traded XBI in the last three years: 2 buys and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Tommy Tuberville R-ALJoint BuyOption $1K–$15K May 8, 2024 filed Jun 14, 2024
  2. Tommy Tuberville R-ALJoint BuyOption $1K–$15K May 8, 2024 filed Jun 14, 2024

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.